The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InEdwards Lifesciences (EW) announced successful 2-year follow-up data from its TRISCEND II clinical trial, bolstering confidence in its medical technologies. The data, presented at the ACC.26 conference, highlights the efficacy of the EVOQUE transcatheter tricuspid valve replacement (TTVR) system in improving patient outcomes. Results demonstrated a significant reduction in all-cause mortality compared to traditional medical therapy over the study period. Furthermore, the trial confirmed the near-complete elimination of tricuspid regurgitation, alongside sustained improvements in patients' overall health status. The findings showed no additional device-related risks, confirming the system's long-term safety profile. This strong clinical evidence strengthens the company's competitive position in the structural heart therapy market and supports future revenue growth expectations.